What reports of GLP-1 benefits beyond weight loss show
US doctors are urging caution over proposed uses for GLP-1 medicines beyond weight management and diabetes, according to reporting by The Epoch Times. As research expands into inflammation, cancer and brain-related conditions, they say emerging findings are not sufficient to justify broad use for these purposes.
The report describes patients who noticed changes in longstanding symptoms while taking the medicines to lose weight. Their experiences offer a reason for further investigation, but cannot establish whether the drugs caused those improvements or whether other patients would benefit.
Jen Weaver, who has rheumatoid arthritis, reported relief from joint pain after starting a GLP-1 medicine. Before treatment, shoulder and hip pain had been waking her twice a night. Restricted exercise and medication side effects had also contributed to weight gain; being able to play on the floor with her grandchildren was an important goal.
Another patient, Sarah Landstrom, told The Epoch Times that painful boils and abscesses associated with hidradenitis suppurativa stopped appearing during nine months of Wegovy use in 2022. She had previously lost weight through diet and exercise without seeing the same improvement in her skin.
According to Landstrom’s account, her dermatologist suspected that something other than weight loss might have contributed. When the skin condition flared again, he suggested returning to a GLP-1 medicine. That remains an individual clinical account, rather than evidence from a controlled trial.
How GLP-1 medicines could influence inflammation
GLP-1 medicines mimic a hormone released by the gut after eating. They help regulate blood glucose, including by stimulating insulin release when glucose levels are raised, and can reduce appetite. Wegovy contains semaglutide, a GLP-1 receptor agonist used for weight management.
The medicines are designed to remain active much longer than the naturally occurring hormone, which the body breaks down rapidly. This allows sustained effects between doses rather than the brief signal produced after a meal.
The Epoch Times describes two possible routes by which treatment could reduce inflammation. One is through weight loss: excess body fat can contribute to chronic, low-grade inflammation, so reducing it may lessen that inflammatory burden.
The other proposed route is a direct effect on inflammatory signalling. The report describes research into GLP-1 receptors on immune cells and whether activating them could reduce the production of inflammatory molecules. How much this contributes to patients’ symptoms, separately from weight loss, remains an open question.
Cancer research raises a similar distinction between indirect benefits and a possible direct drug effect. Small animal studies described in the report have examined changes in tumour metabolism, immune responses and the growth of some tumour cells. Those findings do not establish that GLP-1 medicines prevent or treat cancer in people.
Interest also extends to the brain, where GLP-1 receptors are present. The expanding research agenda includes questions about behaviour, reflected in separate plans to study GLP-1 medicines and impulsive spending. A biological explanation for a possible effect is a starting point for research, not a substitute for demonstrating benefit.
Why doctors are cautious about new GLP-1 uses
Dr Amar Rewari, chief of radiation oncology at Luminis Health and an adjunct assistant professor at Johns Hopkins School of Medicine, told The Epoch Times that he was “cautiously optimistic”. He nevertheless said the newer cancer findings were not sufficient to alter how doctors practise.
Rewari also warned against broad off-label prescribing at this stage. Off-label use means prescribing a medicine outside its authorised indications; the emerging findings discussed in the report do not, by themselves, establish a sound basis for widespread treatment of additional conditions.
Dr Craig Backs, an internist and founder of The CureCenter for Chronic Disease, raised questions about the effects of many years of continuous treatment. His approach, as described in the report, is to refer patients seeking GLP-1 medicines to a weight-loss specialist while continuing to work with them on diet and other contributors to metabolic health.
The safety considerations are not merely theoretical. The report identifies gastrointestinal problems, gallbladder disease and pancreatitis among the risks associated with these medicines. Decisions about treatment also need to account for other prescriptions, a subject explored in our coverage of why GLP-1 use may require a medicines review.
What further GLP-1 research needs to establish
The report calls for more double-blind, placebo-controlled trials to test proposed additional uses. Such trials can help distinguish a treatment effect from changes that would have occurred without the medicine, while systematically recording adverse effects.
For inflammatory conditions, an important question is whether symptom improvements reflect weight loss, a separate pharmacological effect, or both. Landstrom’s experience raises that question, but answering it requires comparisons across groups of patients rather than relying on one person’s treatment history.
The source gives no timetable for new approvals or definitive findings across these proposed uses. For now, patients should not interpret research into cancer or inflammatory disease as evidence that a GLP-1 prescription can replace established care for those conditions. The doctors’ warning against self-prescribing is particularly relevant where the hoped-for benefit remains unproven.
